You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSpironolactone
Accession NumberDB00421  (APRD01234)
TypeSmall Molecule
GroupsApproved
DescriptionA potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
Structure
Thumb
Synonyms
Espironolactona
Spironolactone
Spironolactonum
Spironolattone
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aldactonetablet, film coated25 mg/1oralG.D. Searle LLC Division of Pfizer Inc1960-01-21Not applicableUs
Aldactonetablet, film coated100 mg/1oralG.D. Searle LLC Division of Pfizer Inc1960-01-21Not applicableUs
Aldactonetablet, film coated50 mg/1oralG.D. Searle LLC Division of Pfizer Inc1960-01-21Not applicableUs
Aldactone 100 mgtablet100 mgoralPfizer Canada Inc1975-12-31Not applicableCanada
Aldactone 25 mgtablet25 mgoralPfizer Canada Inc1959-12-31Not applicableCanada
Ntp-spironolactonetablet25 mgoralNt Pharma Canada LtdNot applicableNot applicableCanada
Ntp-spironolactonetablet100 mgoralNt Pharma Canada LtdNot applicableNot applicableCanada
Spironolactonetablet, film coated25 mg/1oralGreenstone LLC1960-01-21Not applicableUs
Spironolactonetablet, film coated50 mg/1oralGreenstone LLC1960-01-21Not applicableUs
Spironolactonetablet, film coated100 mg/1oralGreenstone LLC1960-01-21Not applicableUs
Spironolactonetablet, film coated50 mg/1oralPd Rx Pharmaceuticals, Inc.1960-01-21Not applicableUs
Teva-spironolactonetablet25 mgoralTeva Canada Limited1984-12-31Not applicableCanada
Teva-spironolactonetablet100 mgoralTeva Canada Limited1984-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Spironolactonetablet, film coated100 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-04-15Not applicableUs
Spironolactonetablet, film coated25 mg/1oralREMEDYREPACK INC.2013-06-04Not applicableUs
Spironolactonetablet, film coated25 mg/1oralPhysicians Total Care, Inc.1994-03-25Not applicableUs
Spironolactonetablet, film coated50 mg/1oralbryant ranch prepack1986-07-23Not applicableUs
Spironolactonetablet, film coated50 mg/1oralQualitest Pharmaceuticals2006-08-29Not applicableUs
Spironolactonetablet, film coated25 mg/1oralMc Kesson Contract Packaging2011-12-07Not applicableUs
Spironolactonetablet25 mg/1oralBlenheim Pharmacal, Inc.2014-02-12Not applicableUs
Spironolactonetablet, film coated50 mg/1oralUnit Dose Services1986-07-23Not applicableUs
Spironolactonetablet25 mg/1oralAmneal Pharmaceuticals of New York, LLC2010-08-02Not applicableUs
Spironolactonetablet, film coated25 mg/1oralPd Rx Pharmaceuticals, Inc.2006-08-29Not applicableUs
Spironolactonetablet, film coated50 mg/1oralActavis Pharma, Inc.2007-01-03Not applicableUs
Spironolactonetablet, film coated25 mg/1oralAmerican Health Packaging2010-04-14Not applicableUs
Spironolactonetablet25 mg/1oralAmneal Pharmaceuticals of New York, LLC2010-08-02Not applicableUs
Spironolactonetablet, film coated100 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2001-08-20Not applicableUs
Spironolactonetablet25 mg/1oralREMEDYREPACK INC.2011-10-07Not applicableUs
Spironolactonetablet25 mg/1oralREMEDYREPACK INC.2014-06-24Not applicableUs
Spironolactonetablet, film coated100 mg/1oralCardinal Health2011-02-04Not applicableUs
Spironolactonetablet25 mg/1oralSt Marys Medical Park Pharmacy2013-05-22Not applicableUs
Spironolactonetablet, film coated100 mg/1oralMylan Pharmaceuticals Inc.2002-01-22Not applicableUs
Spironolactonetablet25 mg/1oralPreferred Pharmaceuticals, Inc1994-03-25Not applicableUs
Spironolactonetablet, film coated100 mg/1oralAidarex Pharmaceuticals LLC2006-08-29Not applicableUs
Spironolactonetablet, film coated50 mg/1oralMylan Institutional Inc.2002-02-20Not applicableUs
Spironolactonetablet, film coated25 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Spironolactonetablet25 mg/1oralAvera Mc Kennan Hospital2015-03-24Not applicableUs
Spironolactonetablet, film coated50 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-01-03Not applicableUs
Spironolactonetablet25 mg/1oralREMEDYREPACK INC.2013-05-28Not applicableUs
Spironolactonetablet, film coated50 mg/1oralPhysicians Total Care, Inc.2003-09-11Not applicableUs
Spironolactonetablet50 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2009-08-18Not applicableUs
Spironolactonetablet, film coated100 mg/1oralQualitest Pharmaceuticals2006-08-29Not applicableUs
Spironolactonetablet, film coated25 mg/1oralJubilant Cadista Pharmaceuticals Inc.2013-02-01Not applicableUs
Spironolactonetablet, film coated100 mg/1oralActavis Pharma, Inc.2007-01-03Not applicableUs
Spironolactonetablet, film coated50 mg/1oralAmerican Health Packaging2011-06-10Not applicableUs
Spironolactonetablet25 mg/1oralBlenheim Pharmacal, Inc.2013-10-02Not applicableUs
Spironolactonetablet, film coated100 mg/1oralUnit Dose Services1986-07-23Not applicableUs
Spironolactonetablet50 mg/1oralAmneal Pharmaceuticals of New York, LLC2010-08-02Not applicableUs
Spironolactonetablet50 mg/1oralAmneal Pharmaceuticals of New York, LLC2010-08-02Not applicableUs
Spironolactonetablet25 mg/1oralMajor Pharmaceuticals2009-11-02Not applicableUs
Spironolactonetablet25 mg/1oralREMEDYREPACK INC.2011-05-12Not applicableUs
Spironolactonetablet25 mg/1oralMutual Pharmaceutical Company, Inc.1986-07-23Not applicableUs
Spironolactonetablet, film coated50 mg/1oralCardinal Health2011-02-04Not applicableUs
Spironolactonetablet25 mg/1oralbryant ranch prepack1986-07-23Not applicableUs
Spironolactonetablet, film coated25 mg/1oralMylan Pharmaceuticals Inc.1981-02-03Not applicableUs
Spironolactonetablet, film coated50 mg/1oralPreferred Pharmaceuticals, Inc.2014-10-17Not applicableUs
Spironolactonetablet, film coated25 mg/1oralAidarex Pharmaceuticals LLC2006-08-29Not applicableUs
Spironolactonetablet, film coated100 mg/1oralMylan Institutional Inc.2002-02-20Not applicableUs
Spironolactonetablet25 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Spironolactonetablet25 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-06-01Not applicableUs
Spironolactonetablet, film coated25 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2001-08-20Not applicableUs
Spironolactonetablet, film coated25 mg/1oralA S Medication Solutions2006-08-29Not applicableUs
Spironolactonetablet, film coated25 mg/1oralRebel Distributors Corp2007-01-03Not applicableUs
Spironolactonetablet25 mg/1oralREMEDYREPACK INC.2013-05-28Not applicableUs
Spironolactonetablet, film coated100 mg/1oralPhysicians Total Care, Inc.2004-03-09Not applicableUs
Spironolactonetablet, film coated50 mg/1oralJubilant Cadista Pharmaceuticals Inc.2013-02-01Not applicableUs
Spironolactonetablet, film coated25 mg/1oralActavis Pharma, Inc.2007-01-03Not applicableUs
Spironolactonetablet, film coated100 mg/1oralAmerican Health Packaging2011-06-10Not applicableUs
Spironolactonetablet25 mg/1oralRebel Distributors Corp1986-07-23Not applicableUs
Spironolactonetablet25 mg/1oralUnit Dose Services1986-07-23Not applicableUs
Spironolactonetablet100 mg/1oralAmneal Pharmaceuticals of New York, LLC2010-08-02Not applicableUs
Spironolactonetablet100 mg/1oralAmneal Pharmaceuticals of New York, LLC2010-08-02Not applicableUs
Spironolactonetablet50 mg/1oralMajor Pharmaceuticals2009-11-02Not applicableUs
Spironolactonetablet25 mg/1oralA S Medication Solutions Llc1986-07-23Not applicableUs
Spironolactonetablet, film coated50 mg/1oralMutual Pharmaceutical Company, Inc.1986-07-23Not applicableUs
Spironolactonetablet, film coated25 mg/1oralCardinal Health2011-02-04Not applicableUs
Spironolactonetablet25 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Spironolactonetablet, film coated100 mg/1oralbryant ranch prepack1986-07-23Not applicableUs
Spironolactonetablet, film coated25 mg/1oralQualitest Pharmaceuticals2006-08-29Not applicableUs
Spironolactonetablet25 mg/1oralPreferred Pharmaceuticals, Inc.2012-10-31Not applicableUs
Spironolactonetablet, film coated50 mg/1oralAidarex Pharmaceuticals LLC2006-08-29Not applicableUs
Spironolactonetablet, film coated25 mg/1oralNorthwind Pharmaceuticals, LLC2014-09-15Not applicableUs
Spironolactonetablet50 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-06-01Not applicableUs
Spironolactonetablet, film coated50 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2001-08-20Not applicableUs
Spironolactonetablet, film coated25 mg/1oralSandoz Inc1982-01-01Not applicableUs
Spironolactonetablet25 mg/1oralPd Rx Pharmaceuticals, Inc.2010-08-02Not applicableUs
Spironolactonetablet25 mg/1oralREMEDYREPACK INC.2014-04-16Not applicableUs
Spironolactonetablet25 mg/1oralCardinal Health2011-06-01Not applicableUs
Spironolactonetablet, film coated100 mg/1oralJubilant Cadista Pharmaceuticals Inc.2013-02-01Not applicableUs
Spironolactonetablet, film coated50 mg/1oralMylan Pharmaceuticals Inc.2002-01-22Not applicableUs
Spironolactonetablet, film coated25 mg/1oralCarilion Materials Management2007-01-03Not applicableUs
Spironolactonetablet, film coated50 mg/1oralRebel Distributors Corp2006-08-29Not applicableUs
Spironolactonetablet, film coated25 mg/1oralMylan Institutional Inc.1996-12-23Not applicableUs
Spironolactonetablet, film coated100 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Spironolactonetablet25 mg/1oralAv Pak2011-05-19Not applicableUs
Spironolactonetablet, film coated100 mg/1oralMutual Pharmaceutical Company, Inc.1986-07-23Not applicableUs
Spironolactonetablet, film coated25 mg/1oralCardinal Health2011-05-192016-03-02Us
Spironolactonetablet, film coated25 mg/1oralDispensing Solutions, Inc.2006-08-29Not applicableUs
Spironolactonetablet100 mg/1oralMajor Pharmaceuticals2009-11-02Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
OsyrolNot Available
SpiresisNot Available
SpireticNot Available
SpiroctanNot Available
UractoneNot Available
VerospironNot Available
XenalonNot Available
Brand mixtures
NameLabellerIngredients
AldactazideG.D. Searle LLC Division of Pfizer Inc
Aldactazide 25Pfizer Canada Inc
Aldactazide 50Pfizer Canada Inc
Apo-spirozide TabApotex Inc
Spironolactone and HydrochlorothiazideMylan Pharmaceuticals Inc.
Teva-spironolactone/hctzTeva Canada Limited
SaltsNot Available
Categories
UNII27O7W4T232
CAS number52-01-7
WeightAverage: 416.573
Monoisotopic: 416.202130202
Chemical FormulaC24H32O4S
InChI KeyInChIKey=LXMSZDCAJNLERA-ZHYRCANASA-N
InChI
InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1
IUPAC Name
(1'S,2R,2'R,9'R,10'R,11'S,15'S)-9'-(acetylsulfanyl)-2',15'-dimethylspiro[oxolane-2,14'-tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan]-6'-ene-5,5'-dione
SMILES
[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as spironolactones and derivatives. These are steroid lactones with a structure based on the spironolactone skeleton.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSteroid lactones
Direct ParentSpironolactones and derivatives
Alternative Parents
Substituents
  • Spironolactone
  • Oxosteroid
  • 3-oxosteroid
  • 3-oxo-delta-4-steroid
  • Delta-4-steroid
  • Gamma butyrolactone
  • Oxolane
  • Cyclic ketone
  • Thiocarboxylic acid ester
  • Lactone
  • Ketone
  • Carboxylic acid ester
  • Oxacycle
  • Organoheterocyclic compound
  • Sulfenyl compound
  • Thioether
  • Thiocarboxylic acid or derivatives
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Carbonyl group
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationUsed primarily to treat low-renin hypertension, hypokalemia, and Conn's syndrome.
PharmacodynamicsSpironolactone is a synthetic 17-lactone steroid which is a renal competitive aldosterone antagonist in a class of pharmaceuticals called potassium-sparing diuretics. On its own, spironolactone is only a weak diuretic, but it can be combined with other diuretics. Due to its anti-androgen effect, it can also be used to treat hirsutism, and is a common component in hormone therapy for male-to-female transgendered people. Spironolactone inhibits the effect of aldosterone by competing for intracellular aldosterone receptor in the distal tubule cells. This increases the secretion of water and sodium, while decreasing the excretion of potassium. Spironolactone has a fairly slow onset of action, taking several days to develop and similarly the effect diminishes slowly.
Mechanism of actionSpironolactone is a specific pharmacologic antagonist of aldosterone, acting primarily through competitive binding of receptors at the aldosterone-dependent sodium-potassium exchange site in the distal convoluted renal tubule. Spironolactone causes increased amounts of sodium and water to be excreted, while potassium is retained. Spironolactone acts both as a diuretic and as an antihypertensive drug by this mechanism. It may be given alone or with other diuretic agents which act more proximally in the renal tubule. Aldosterone interacts with a cytoplasmic mineralocorticoid receptor to enhance the expression of the Na+, K+-ATPase and the Na+ channel involved in a Na+ K+ transport in the distal tubule . Spironolactone bind to this mineralcorticoid receptor, blocking the actions of aldosterone on gene expression. Aldosterone is a hormone; its primary function is to retain sodium and excrete potassium in the kidneys.
Related Articles
AbsorptionFairly rapidly absorbed from the gastrointestinal tract. Food increases the bioavailability of unmetabolized spironolactone by almost 100%.
Volume of distributionNot Available
Protein bindingSpironolactone and its metabolites are more than 90% bound to plasma proteins.
Metabolism

Rapidly and extensively metabolized. The metabolic pathway of spironolactone is complex and can be divided into two main routes: those in which the sulfur moiety is retained and those in which the sulfur moiety is removed by dethioacetylation. Spironolactone is transformed to a reactive metabolite that can inactivate adrenal and testicular cytochrome P450 enzymes. It also has anti-androgenic activity.

Route of eliminationThe metabolites are excreted primarily in the urine and secondarily in bile.
Half life10 minutes
ClearanceNot Available
ToxicityThe oral LD50 of spironolactone is greater than 1,000 mg/kg in mice, rats, and rabbits. Acute overdosage of spironolactone may be manifested by drowsiness, mental confusion, maculopapular or erythematous rash, nausea, vomiting, dizziness, or diarrhea. Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Spironolactone Action PathwayDrug actionSMP00134
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9912
Blood Brain Barrier+0.932
Caco-2 permeable+0.5432
P-glycoprotein substrateSubstrate0.5691
P-glycoprotein inhibitor IInhibitor0.6807
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterNon-inhibitor0.727
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6638
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9276
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8681
Ames testNon AMES toxic0.9158
CarcinogenicityNon-carcinogens0.9288
BiodegradationNot ready biodegradable0.9696
Rat acute toxicity2.0150 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9427
hERG inhibition (predictor II)Non-inhibitor0.7002
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Gd searle llc
  • Actavis elizabeth llc
  • Amneal pharmaceuticals
  • Ascot hosp pharmaceuticals inc div travenol laboratories inc
  • Ivax pharmaceuticals inc
  • Lederle laboratories div american cyanamid co
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Purepac pharmaceutical co
  • Sandoz inc
  • Superpharm corp
  • Upsher smith laboratories inc
  • Vangard laboratories inc div midway medical co
  • Vintage pharmaceuticals llc
  • Warner chilcott div warner lambert co
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedoral
Tablet, film coatedoral100 mg/1
Tablet, film coatedoral25 mg/1
Tablet, film coatedoral50 mg/1
Tabletoral100 mg
Tabletoral25 mg
Tabletoral100 mg/1
Tabletoral25 mg/1
Tabletoral50 mg/1
Tabletoral
Prices
Unit descriptionCostUnit
Spironolactone powder12.56USD g
Aldactone 100 mg tablet2.14USD tablet
Aldactazide 50-50 mg tablet2.02USD tablet
Aldactazide 50-50 tablet1.92USD tablet
Aldactone 50 mg tablet1.84USD tablet
Spironolactone 100 mg tablet1.45USD tablet
Aldactazide 25-25 mg tablet1.26USD tablet
Aldactazide 25-25 tablet1.04USD tablet
Spironolactone 50 mg tablet0.83USD tablet
Aldactone 25 mg tablet0.8USD tablet
Spironolactone-HCTZ 25-25 mg tablet0.57USD tablet
Spironolactone 25 mg tablet0.5USD tablet
Novo-Spiroton 100 mg Tablet0.25USD tablet
Novo-Spiroton 25 mg Tablet0.11USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point134.5 °CPhysProp
water solubility22 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.78HANSCH,C ET AL. (1995)
logS-4.28ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00198 mg/mLALOGPS
logP3.1ALOGPS
logP3.64ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)18.01ChemAxon
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area60.44 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity113.5 m3·mol-1ChemAxon
Polarizability46.03 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0006-9836000000-9f600bd39c3b914c0b17View in MoNA
References
Synthesis Reference

Giuseppe Bernini, “Process for preparing micronized spironolactone.” U.S. Patent US4332721, issued July, 1975.

US4332721
General References
  1. Berardesca E, Gabba P, Ucci G, Borroni G, Rabbiosi G: Topical spironolactone inhibits dihydrotestosterone receptors in human sebaceous glands: an autoradiographic study in subjects with acne vulgaris. Int J Tissue React. 1988;10(2):115-9. [PubMed:2972662 ]
  2. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 2;341(10):709-17. [PubMed:10471456 ]
  3. Wandelt-Freerksen E: [Aldactone in the treatment of sarcoidosis of the lungs (author's transl)]. Z Erkr Atmungsorgane. 1977 Jul;149(1):156-9. [PubMed:607621 ]
External Links
ATC CodesC03DA01
AHFS Codes
  • 24:32.20
PDB EntriesNot Available
FDA labelDownload (395 KB)
MSDSDownload (72.6 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe therapeutic efficacy of Abiraterone can be decreased when used in combination with Spironolactone.
AcebutololThe risk or severity of adverse effects can be increased when Spironolactone is combined with Acebutolol.
AceclofenacAceclofenac may decrease the antihypertensive activities of Spironolactone.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Spironolactone.
AcetazolamideThe risk or severity of adverse effects can be increased when Spironolactone is combined with Acetazolamide.
AcetyldigitoxinThe therapeutic efficacy of Acetyldigitoxin can be decreased when used in combination with Spironolactone.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Spironolactone.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Spironolactone.
AdapaleneAdapalene may decrease the antihypertensive activities of Spironolactone.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Spironolactone.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Spironolactone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Spironolactone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Spironolactone.
AliskirenThe risk or severity of adverse effects can be increased when Spironolactone is combined with Aliskiren.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Spironolactone.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Spironolactone.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Spironolactone.
AmilorideAmiloride may increase the hyperkalemic activities of Spironolactone.
AmilorideThe risk or severity of adverse effects can be increased when Spironolactone is combined with Amiloride.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Spironolactone.
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Spironolactone.
Ammonium chlorideThe risk or severity of adverse effects can be increased when Spironolactone is combined with Ammonium chloride.
AmobarbitalAmobarbital may increase the hypotensive activities of Spironolactone.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Spironolactone.
Amyl NitriteThe risk or severity of adverse effects can be increased when Spironolactone is combined with Amyl Nitrite.
AntipyrineAntipyrine may decrease the antihypertensive activities of Spironolactone.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Spironolactone.
ApraclonidineThe risk or severity of adverse effects can be increased when Spironolactone is combined with Apraclonidine.
ApremilastApremilast may decrease the antihypertensive activities of Spironolactone.
ArdeparinArdeparin may increase the hyperkalemic activities of Spironolactone.
AripiprazoleAripiprazole may increase the hypotensive activities of Spironolactone.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Spironolactone.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Spironolactone.
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Spironolactone.
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Spironolactone.
Atracurium besylateSpironolactone may increase the neuromuscular blocking activities of Atracurium besylate.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Spironolactone.
AzapropazoneAzapropazone may decrease the antihypertensive activities of Spironolactone.
AzelastineAzelastine may decrease the antihypertensive activities of Spironolactone.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Spironolactone is combined with Azilsartan medoxomil.
BalsalazideBalsalazide may decrease the antihypertensive activities of Spironolactone.
BarbitalBarbital may increase the hypotensive activities of Spironolactone.
BemiparinBemiparin may increase the hyperkalemic activities of Spironolactone.
BenazeprilThe risk or severity of adverse effects can be increased when Spironolactone is combined with Benazepril.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Spironolactone is combined with Bendroflumethiazide.
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Spironolactone.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Spironolactone.
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Spironolactone.
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Spironolactone.
BisoprololThe risk or severity of adverse effects can be increased when Spironolactone is combined with Bisoprolol.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Spironolactone.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Spironolactone.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Spironolactone.
BretyliumThe risk or severity of adverse effects can be increased when Spironolactone is combined with Bretylium.
BrimonidineThe risk or severity of adverse effects can be increased when Spironolactone is combined with Brimonidine.
BromfenacBromfenac may decrease the antihypertensive activities of Spironolactone.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Spironolactone.
BumetanideThe risk or severity of adverse effects can be increased when Spironolactone is combined with Bumetanide.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Spironolactone.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Spironolactone.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Spironolactone.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Spironolactone.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Spironolactone.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Spironolactone.
CanagliflozinThe risk or severity of adverse effects can be increased when Spironolactone is combined with Canagliflozin.
CandesartanThe risk or severity of adverse effects can be increased when Spironolactone is combined with Candesartan.
CandoxatrilSpironolactone may increase the hyperkalemic activities of Candoxatril.
CaptoprilThe risk or severity of adverse effects can be increased when Spironolactone is combined with Captopril.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Spironolactone.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Spironolactone.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Spironolactone.
CarprofenCarprofen may decrease the antihypertensive activities of Spironolactone.
CarteololThe risk or severity of adverse effects can be increased when Spironolactone is combined with Carteolol.
CarvedilolThe risk or severity of adverse effects can be increased when Spironolactone is combined with Carvedilol.
CastanospermineCastanospermine may decrease the antihypertensive activities of Spironolactone.
CelecoxibCelecoxib may decrease the antihypertensive activities of Spironolactone.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Spironolactone.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Spironolactone.
CertoparinCertoparin may increase the hyperkalemic activities of Spironolactone.
ChloroquineChloroquine may decrease the antihypertensive activities of Spironolactone.
ChlorothiazideThe risk or severity of adverse effects can be increased when Spironolactone is combined with Chlorothiazide.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Spironolactone.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Spironolactone.
CholestyramineThe risk or severity of adverse effects can be increased when Cholestyramine is combined with Spironolactone.
CilazaprilThe risk or severity of adverse effects can be increased when Spironolactone is combined with Cilazapril.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Spironolactone.
CiprofloxacinSpironolactone may increase the arrhythmogenic activities of Ciprofloxacin.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Spironolactone.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Spironolactone.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Spironolactone.
ClevidipineThe risk or severity of adverse effects can be increased when Spironolactone is combined with Clevidipine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Spironolactone.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Spironolactone.
ClonidineThe risk or severity of adverse effects can be increased when Spironolactone is combined with Clonidine.
ClonixinClonixin may decrease the antihypertensive activities of Spironolactone.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Spironolactone.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Spironolactone.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Spironolactone.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Spironolactone.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Spironolactone.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Spironolactone.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Spironolactone.
CyclosporineSpironolactone may increase the hyperkalemic activities of Cyclosporine.
D-LimoneneD-Limonene may decrease the antihypertensive activities of Spironolactone.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Spironolactone.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Spironolactone.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Spironolactone.
DalteparinDalteparin may increase the hyperkalemic activities of Spironolactone.
DapagliflozinThe risk or severity of adverse effects can be increased when Spironolactone is combined with Dapagliflozin.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Spironolactone.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Spironolactone.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Spironolactone.
DeslanosideThe therapeutic efficacy of Deslanoside can be decreased when used in combination with Spironolactone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Spironolactone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Spironolactone is combined with Dexmedetomidine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Spironolactone.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Spironolactone.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Spironolactone.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Spironolactone.
DiclofenacDiclofenac may decrease the antihypertensive activities of Spironolactone.
DiclofenamideThe risk or severity of adverse effects can be increased when Spironolactone is combined with Diclofenamide.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Spironolactone.
DiflunisalDiflunisal may decrease the antihypertensive activities of Spironolactone.
DigitoxinThe therapeutic efficacy of Digitoxin can be decreased when used in combination with Spironolactone.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Spironolactone.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Spironolactone.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Spironolactone.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Spironolactone.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Spironolactone.
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Spironolactone.
DinutuximabThe risk or severity of adverse effects can be increased when Spironolactone is combined with Dinutuximab.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Spironolactone.
DipyridamoleThe risk or severity of adverse effects can be increased when Spironolactone is combined with Dipyridamole.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Spironolactone.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Spironolactone.
DoxazosinThe risk or severity of adverse effects can be increased when Spironolactone is combined with Doxazosin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Spironolactone.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Spironolactone.
DrospirenoneDrospirenone may increase the hyperkalemic activities of Spironolactone.
DroxicamDroxicam may decrease the antihypertensive activities of Spironolactone.
DuloxetineSpironolactone may increase the orthostatic hypotensive activities of Duloxetine.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Spironolactone.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Spironolactone.
EmpagliflozinThe risk or severity of adverse effects can be increased when Spironolactone is combined with Empagliflozin.
EnalaprilThe risk or severity of adverse effects can be increased when Spironolactone is combined with Enalapril.
EnalaprilatSpironolactone may increase the hyperkalemic activities of Enalaprilat.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Spironolactone.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Spironolactone.
EpirizoleEpirizole may decrease the antihypertensive activities of Spironolactone.
EplerenoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Eplerenone.
EprosartanThe risk or severity of adverse effects can be increased when Spironolactone is combined with Eprosartan.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Spironolactone.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Spironolactone.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Spironolactone.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Spironolactone.
EstriolThe serum concentration of Estriol can be increased when it is combined with Spironolactone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Spironolactone.
Etacrynic acidThe risk or severity of adverse effects can be increased when Spironolactone is combined with Etacrynic acid.
EtanerceptEtanercept may decrease the antihypertensive activities of Spironolactone.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Spironolactone.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Spironolactone.
EtodolacEtodolac may decrease the antihypertensive activities of Spironolactone.
EtofenamateEtofenamate may decrease the antihypertensive activities of Spironolactone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Spironolactone.
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Spironolactone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Spironolactone.
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Spironolactone.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Spironolactone.
exisulindexisulind may decrease the antihypertensive activities of Spironolactone.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Spironolactone.
FelodipineThe risk or severity of adverse effects can be increased when Spironolactone is combined with Felodipine.
FenbufenFenbufen may decrease the antihypertensive activities of Spironolactone.
FenoprofenFenoprofen may decrease the antihypertensive activities of Spironolactone.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Spironolactone.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Spironolactone.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Spironolactone.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Spironolactone.
FloctafenineFloctafenine may decrease the antihypertensive activities of Spironolactone.
FlunixinFlunixin may decrease the antihypertensive activities of Spironolactone.
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Spironolactone.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Spironolactone.
ForasartanForasartan may increase the hyperkalemic activities of Spironolactone.
FosinoprilThe risk or severity of adverse effects can be increased when Spironolactone is combined with Fosinopril.
FurosemideThe risk or severity of adverse effects can be increased when Spironolactone is combined with Furosemide.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Spironolactone.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Spironolactone.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Spironolactone.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Spironolactone.
GuanfacineThe risk or severity of adverse effects can be increased when Spironolactone is combined with Guanfacine.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Spironolactone.
HeparinHeparin may increase the hyperkalemic activities of Spironolactone.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Spironolactone.
HexobarbitalHexobarbital may increase the hypotensive activities of Spironolactone.
HMPL-004HMPL-004 may decrease the antihypertensive activities of Spironolactone.
HydralazineThe risk or severity of adverse effects can be increased when Spironolactone is combined with Hydralazine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Spironolactone is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Spironolactone.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Spironolactone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Spironolactone.
IbuprofenIbuprofen may decrease the antihypertensive activities of Spironolactone.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Spironolactone.
IbuproxamIbuproxam may decrease the antihypertensive activities of Spironolactone.
IcatibantIcatibant may decrease the antihypertensive activities of Spironolactone.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Spironolactone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Spironolactone.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Spironolactone.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Spironolactone.
IndapamideThe risk or severity of adverse effects can be increased when Spironolactone is combined with Indapamide.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Spironolactone.
IndomethacinIndomethacin may decrease the antihypertensive activities of Spironolactone.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Spironolactone.
IndoprofenIndoprofen may decrease the antihypertensive activities of Spironolactone.
IrbesartanThe risk or severity of adverse effects can be increased when Spironolactone is combined with Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Spironolactone.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Spironolactone is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Spironolactone is combined with Isosorbide Mononitrate.
IsoxicamIsoxicam may decrease the antihypertensive activities of Spironolactone.
IsoxsuprineThe risk or severity of adverse effects can be increased when Spironolactone is combined with Isoxsuprine.
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Spironolactone.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Spironolactone.
KebuzoneKebuzone may decrease the antihypertensive activities of Spironolactone.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Spironolactone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Spironolactone.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Spironolactone.
KetoprofenKetoprofen may decrease the antihypertensive activities of Spironolactone.
KetorolacKetorolac may decrease the antihypertensive activities of Spironolactone.
LabetalolThe risk or severity of adverse effects can be increased when Spironolactone is combined with Labetalol.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Spironolactone.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Spironolactone.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Spironolactone.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Spironolactone.
LeflunomideLeflunomide may decrease the antihypertensive activities of Spironolactone.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Spironolactone.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Spironolactone.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Spironolactone.
LevobunololThe risk or severity of adverse effects can be increased when Spironolactone is combined with Levobunolol.
LevodopaSpironolactone may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Spironolactone.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Spironolactone.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Spironolactone.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Spironolactone.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Spironolactone.
LisinoprilThe risk or severity of adverse effects can be increased when Spironolactone is combined with Lisinopril.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Spironolactone.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Spironolactone.
LornoxicamLornoxicam may decrease the antihypertensive activities of Spironolactone.
LosartanThe risk or severity of adverse effects can be increased when Spironolactone is combined with Losartan.
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Spironolactone.
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Spironolactone.
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Spironolactone.
MannitolThe risk or severity of adverse effects can be increased when Spironolactone is combined with Mannitol.
MasoprocolMasoprocol may decrease the antihypertensive activities of Spironolactone.
MecamylamineThe risk or severity of adverse effects can be increased when Spironolactone is combined with Mecamylamine.
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Spironolactone.
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Spironolactone.
MeloxicamMeloxicam may decrease the antihypertensive activities of Spironolactone.
MesalazineMesalazine may decrease the antihypertensive activities of Spironolactone.
MetamizoleMetamizole may decrease the antihypertensive activities of Spironolactone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Spironolactone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Spironolactone.
MethazolamideThe risk or severity of adverse effects can be increased when Spironolactone is combined with Methazolamide.
MethohexitalMethohexital may increase the hypotensive activities of Spironolactone.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Spironolactone.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Spironolactone.
MethyldopaThe risk or severity of adverse effects can be increased when Spironolactone is combined with Methyldopa.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Spironolactone.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Spironolactone.
MetipranololThe risk or severity of adverse effects can be increased when Spironolactone is combined with Metipranolol.
MetolazoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Metolazone.
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Spironolactone.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Spironolactone.
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Spironolactone.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Spironolactone.
MitotaneThe therapeutic efficacy of Mitotane can be decreased when used in combination with Spironolactone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Spironolactone.
MivacuriumSpironolactone may increase the neuromuscular blocking activities of Mivacurium.
MoexiprilThe risk or severity of adverse effects can be increased when Spironolactone is combined with Moexipril.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Spironolactone.
MorphineThe serum concentration of Morphine can be increased when it is combined with Spironolactone.
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Spironolactone.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Spironolactone.
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Spironolactone.
NabumetoneNabumetone may decrease the antihypertensive activities of Spironolactone.
NadololThe risk or severity of adverse effects can be increased when Spironolactone is combined with Nadolol.
NadroparinNadroparin may increase the hyperkalemic activities of Spironolactone.
NaftifineNaftifine may decrease the antihypertensive activities of Spironolactone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Spironolactone.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Spironolactone.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Spironolactone.
NaproxenNaproxen may decrease the antihypertensive activities of Spironolactone.
NCX 4016NCX 4016 may decrease the antihypertensive activities of Spironolactone.
NebivololThe risk or severity of adverse effects can be increased when Spironolactone is combined with Nebivolol.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Spironolactone.
NepafenacNepafenac may decrease the antihypertensive activities of Spironolactone.
NesiritideThe risk or severity of adverse effects can be increased when Spironolactone is combined with Nesiritide.
NicardipineThe risk or severity of adverse effects can be increased when Spironolactone is combined with Nicardipine.
NicorandilNicorandil may increase the hypotensive activities of Spironolactone.
NifedipineThe risk or severity of adverse effects can be increased when Spironolactone is combined with Nifedipine.
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Spironolactone.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Spironolactone.
NimesulideNimesulide may decrease the antihypertensive activities of Spironolactone.
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Spironolactone.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Spironolactone.
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Spironolactone.
NitrofurantoinNitrofurantoin may increase the hyperkalemic activities of Spironolactone.
NitroglycerinThe risk or severity of adverse effects can be increased when Spironolactone is combined with Nitroglycerin.
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Spironolactone.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Spironolactone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Spironolactone.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Spironolactone.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Spironolactone.
OlopatadineOlopatadine may decrease the antihypertensive activities of Spironolactone.
OlsalazineOlsalazine may decrease the antihypertensive activities of Spironolactone.
OmapatrilatSpironolactone may increase the hyperkalemic activities of Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Spironolactone.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Spironolactone.
OrgoteinOrgotein may decrease the antihypertensive activities of Spironolactone.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Spironolactone.
OuabainThe therapeutic efficacy of Ouabain can be decreased when used in combination with Spironolactone.
OxaprozinOxaprozin may decrease the antihypertensive activities of Spironolactone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Spironolactone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Spironolactone.
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Spironolactone.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Spironolactone.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Spironolactone.
PapaverineThe risk or severity of adverse effects can be increased when Spironolactone is combined with Papaverine.
ParecoxibParecoxib may decrease the antihypertensive activities of Spironolactone.
ParnaparinParnaparin may increase the hyperkalemic activities of Spironolactone.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Spironolactone.
PenbutololThe risk or severity of adverse effects can be increased when Spironolactone is combined with Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Spironolactone.
PentobarbitalPentobarbital may increase the hypotensive activities of Spironolactone.
PerindoprilThe risk or severity of adverse effects can be increased when Spironolactone is combined with Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Spironolactone.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Spironolactone.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Spironolactone.
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Spironolactone.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Spironolactone.
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Spironolactone.
PindololThe risk or severity of adverse effects can be increased when Spironolactone is combined with Pindolol.
PirfenidonePirfenidone may decrease the antihypertensive activities of Spironolactone.
PiroxicamPiroxicam may decrease the antihypertensive activities of Spironolactone.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Spironolactone.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Spironolactone.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Spironolactone.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Spironolactone.
PrazosinThe risk or severity of adverse effects can be increased when Spironolactone is combined with Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Spironolactone.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Spironolactone.
PrimidonePrimidone may increase the hypotensive activities of Spironolactone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Spironolactone.
PropacetamolPropacetamol may decrease the antihypertensive activities of Spironolactone.
PropranololThe risk or severity of adverse effects can be increased when Spironolactone is combined with Propranolol.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Spironolactone.
PTC299PTC299 may decrease the antihypertensive activities of Spironolactone.
QuetiapineThe risk or severity of adverse effects can be increased when Spironolactone is combined with Quetiapine.
QuinaprilThe risk or severity of adverse effects can be increased when Spironolactone is combined with Quinapril.
QuinidineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Spironolactone.
QuinineThe serum concentration of Quinine can be increased when it is combined with Spironolactone.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Spironolactone.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Spironolactone.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Spironolactone.
RapacuroniumSpironolactone may increase the neuromuscular blocking activities of Rapacuronium.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Spironolactone.
RescinnamineSpironolactone may increase the hyperkalemic activities of Rescinnamine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Spironolactone.
ResveratrolResveratrol may decrease the antihypertensive activities of Spironolactone.
ReviparinReviparin may increase the hyperkalemic activities of Spironolactone.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Spironolactone.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Spironolactone.
RiociguatThe risk or severity of adverse effects can be increased when Spironolactone is combined with Riociguat.
RisperidoneSpironolactone may increase the hypotensive activities of Risperidone.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Spironolactone.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Spironolactone.
RofecoxibRofecoxib may decrease the antihypertensive activities of Spironolactone.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Spironolactone.
SalicylamideSalicylamide may decrease the antihypertensive activities of Spironolactone.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Spironolactone.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Spironolactone.
SalsalateSalsalate may decrease the antihypertensive activities of Spironolactone.
SaprisartanSaprisartan may increase the hyperkalemic activities of Spironolactone.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Spironolactone.
SaralasinSaralasin may increase the hyperkalemic activities of Spironolactone.
SecobarbitalSecobarbital may increase the hypotensive activities of Spironolactone.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Spironolactone.
SeratrodastSeratrodast may decrease the antihypertensive activities of Spironolactone.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Spironolactone.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Spironolactone.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Spironolactone.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Spironolactone.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Spironolactone.
SotalolThe risk or severity of adverse effects can be increased when Spironolactone is combined with Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Spironolactone.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Spironolactone.
SpiraprilSpironolactone may increase the hyperkalemic activities of Spirapril.
SRT501SRT501 may decrease the antihypertensive activities of Spironolactone.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Spironolactone.
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Spironolactone.
SulindacSulindac may decrease the antihypertensive activities of Spironolactone.
SuprofenSuprofen may decrease the antihypertensive activities of Spironolactone.
TacrolimusSpironolactone may increase the hyperkalemic activities of Tacrolimus.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Spironolactone.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Spironolactone.
TasosartanTasosartan may increase the hyperkalemic activities of Spironolactone.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Spironolactone.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Spironolactone.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Spironolactone.
TelmisartanThe risk or severity of adverse effects can be increased when Spironolactone is combined with Telmisartan.
TemocaprilSpironolactone may increase the hyperkalemic activities of Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Spironolactone.
TenoxicamTenoxicam may decrease the antihypertensive activities of Spironolactone.
TepoxalinTepoxalin may decrease the antihypertensive activities of Spironolactone.
TerazosinThe risk or severity of adverse effects can be increased when Spironolactone is combined with Terazosin.
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Spironolactone.
ThiamylalThiamylal may increase the hypotensive activities of Spironolactone.
ThiopentalThiopental may increase the hypotensive activities of Spironolactone.
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Spironolactone.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Spironolactone.
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Spironolactone.
TinzaparinTinzaparin may increase the hyperkalemic activities of Spironolactone.
TizanidineThe risk or severity of adverse effects can be increased when Spironolactone is combined with Tizanidine.
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Spironolactone.
TolmetinTolmetin may decrease the antihypertensive activities of Spironolactone.
TolvaptanTolvaptan may increase the hyperkalemic activities of Spironolactone.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Spironolactone.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Spironolactone.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Spironolactone.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Spironolactone.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Spironolactone.
TrandolaprilThe risk or severity of adverse effects can be increased when Spironolactone is combined with Trandolapril.
TranilastTranilast may decrease the antihypertensive activities of Spironolactone.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Spironolactone.
TriamtereneTriamterene may increase the hyperkalemic activities of Spironolactone.
TriamtereneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Triamterene.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Spironolactone.
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Spironolactone.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Spironolactone.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Spironolactone.
ValdecoxibValdecoxib may decrease the antihypertensive activities of Spironolactone.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Spironolactone.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Spironolactone.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Spironolactone.
VerapamilThe risk or severity of adverse effects can be increased when Spironolactone is combined with Verapamil.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Spironolactone.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Spironolactone.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Spironolactone.
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Spironolactone.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Spironolactone.
ZileutonZileuton may decrease the antihypertensive activities of Spironolactone.
ZomepiracZomepirac may decrease the antihypertensive activities of Spironolactone.
Food Interactions
  • Avoid alcohol.
  • Food increases the bioavailability of spironolactone by almost 100%.
  • Spironolactone may decrease the excretion of potassium. Salt substitutes containing potassium increase the risk of hyperkalemia.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates target genes. The effect of MC is to increase ion and water transport and thus raise extracellular fluid volume and blood pressure and lower potassium levels.
Gene Name:
NR3C2
Uniprot ID:
P08235
Molecular Weight:
107066.575 Da
References
  1. Sitruk-Ware R: Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause. 2002 Jan-Feb;9(1):6-15. [PubMed:11791081 ]
  2. Rogerson FM, Yao YZ, Smith BJ, Dimopoulos N, Fuller PJ: Determinants of spironolactone binding specificity in the mineralocorticoid receptor. J Mol Endocrinol. 2003 Dec;31(3):573-82. [PubMed:14664717 ]
  3. Gertner RA, Klein JD, Bailey JL, Kim DU, Luo XH, Bagnasco SM, Sands JM: Aldosterone decreases UT-A1 urea transporter expression via the mineralocorticoid receptor. J Am Soc Nephrol. 2004 Mar;15(3):558-65. [PubMed:14978157 ]
  4. Frishman WH, Stier CT Jr: Aldosterone and aldosterone antagonism in systemic hypertension. Curr Hypertens Rep. 2004 Jun;6(3):195-200. [PubMed:15128471 ]
  5. Rogerson FM, Yao Y, Smith BJ, Fuller PJ: Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor. Clin Exp Pharmacol Physiol. 2004 Oct;31(10):704-9. [PubMed:15554912 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Sica DA: Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev. 2005 Jan;10(1):23-9. [PubMed:15947888 ]
  8. Rossi G, Boscaro M, Ronconi V, Funder JW: Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab. 2005 Apr;16(3):104-7. [PubMed:15808807 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3.
Gene Name:
AR
Uniprot ID:
P10275
Molecular Weight:
98987.9 Da
References
  1. Ye P, Yamashita T, Pollock DM, Sasano H, Rainey WE: Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis. Horm Metab Res. 2009 Jan;41(1):35-9. doi: 10.1055/s-0028-1087188. Epub 2008 Sep 25. [PubMed:18819053 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor isoform B (PRB) is involved activation of c-SRC/MAPK signaling on hormone stimulation.Isoform A: inactive in stimulating c-Src/MAPK signaling on hormone stimulation.Isoform 4: Increases mitochondrial ...
Gene Name:
PGR
Uniprot ID:
P06401
Molecular Weight:
98979.96 Da
References
  1. Fagart J, Hillisch A, Huyet J, Barfacker L, Fay M, Pleiss U, Pook E, Schafer S, Rafestin-Oblin ME, Kolkhof P: A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010 Sep 24;285(39):29932-40. doi: 10.1074/jbc.M110.131342. Epub 2010 Jul 22. [PubMed:20650892 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Fagart J, Hillisch A, Huyet J, Barfacker L, Fay M, Pleiss U, Pook E, Schafer S, Rafestin-Oblin ME, Kolkhof P: A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010 Sep 24;285(39):29932-40. doi: 10.1074/jbc.M110.131342. Epub 2010 Jul 22. [PubMed:20650892 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Steroid 11-beta-monooxygenase activity
Specific Function:
Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone.
Gene Name:
CYP11B2
Uniprot ID:
P19099
Molecular Weight:
57559.62 Da
References
  1. Cheng SC, Suzuki K, Sadee W, Harding BW: Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria. Endocrinology. 1976 Oct;99(4):1097-106. [PubMed:976190 ]
6. 17alpha-hydroxylase
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
References
  1. Authors unspecified: Spironolactone and endocrine dysfunction. Ann Intern Med. 1976 Nov;85(5):630-6. [PubMed:984618 ]
  2. Desai; Meena P.; Vijayalakshmi Bhatia & P.S.N. Menon (2001). Pediatric Endocrine Disorders. Orient Blackswan. [ISBN:978-81-250-2025-7 ]
7. 17,20-desmolase
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
References
  1. Authors unspecified: Spironolactone and endocrine dysfunction. Ann Intern Med. 1976 Nov;85(5):630-6. [PubMed:984618 ]
  2. Desai; Meena P.; Vijayalakshmi Bhatia & P.S.N. Menon (2001). Pediatric Endocrine Disorders. Orient Blackswan. [ISBN:978-81-250-2025-7 ]
Kind
Protein group
Organism
Pharmacological action
unknown
Actions
antagonist
General Function:
Electron carrier activity
Specific Function:
Converts testosterone into 5-alpha-dihydrotestosterone and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology.
Components:
NameUniProt IDDetails
3-oxo-5-alpha-steroid 4-dehydrogenase 1P18405 Details
3-oxo-5-alpha-steroid 4-dehydrogenase 2P31213 Details
Polyprenol reductaseQ9H8P0 Details
References
  1. Corvol P, Michaud A, Menard J, Freifeld M, Mahoudeau J: Antiandrogenic effect of spirolactones: mechanism of action. Endocrinology. 1975 Jul;97(1):52-8. [PubMed:166833 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Androgen binding
Specific Function:
Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone, and 17-beta-estradiol. Regulates the plasma metabolic clearance rate of steroid hormones by controlling their plasma concentration.
Gene Name:
SHBG
Uniprot ID:
P04278
Molecular Weight:
43778.755 Da
References
  1. Braunstein GD: Clinical practice. Gynecomastia. N Engl J Med. 2007 Sep 20;357(12):1229-37. [PubMed:17881754 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated calcium channel activity
Specific Function:
This protein is a subunit of the dihydropyridine (DHP) sensitive calcium channel. Plays a role in excitation-contraction coupling. The skeletal muscle DHP-sensitive Ca(2+) channel may function only as a multiple subunit complex.
Gene Name:
CACNG1
Uniprot ID:
Q06432
Molecular Weight:
25028.105 Da
References
  1. Sorrentino R, Autore G, Cirino G, d'Emmanuele de Villa Bianca R, Calignano A, Vanasia M, Alfieri C, Sorrentino L, Pinto A: Effect of spironolactone and its metabolites on contractile property of isolated rat aorta rings. J Cardiovasc Pharmacol. 2000 Aug;36(2):230-5. [PubMed:10942165 ]
  2. Melander A, Danielson K, Schersten B, Thulin T, Wahlin E: Enhancement by food of canrenone bioavailability from spironolactone. Clin Pharmacol Ther. 1977 Jul;22(1):100-3. [PubMed:872489 ]
11. Dihydrotestosterone receptor
Kind
Protein
Organism
Human
Pharmacological action
unknown
References
  1. Berardesca E, Gabba P, Ucci G, Borroni G, Rabbiosi G: Topical spironolactone inhibits dihydrotestosterone receptors in human sebaceous glands: an autoradiographic study in subjects with acne vulgaris. Int J Tissue React. 1988;10(2):115-9. [PubMed:2972662 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Steroid 11-beta-monooxygenase activity
Specific Function:
Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochrome P450 XIB.
Gene Name:
CYP11B1
Uniprot ID:
P15538
Molecular Weight:
57572.44 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Cheng SC, Suzuki K, Sadee W, Harding BW: Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria. Endocrinology. 1976 Oct;99(4):1097-106. [PubMed:976190 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Johnson DR, Klaassen CD: Regulation of rat multidrug resistance protein 2 by classes of prototypical microsomal enzyme inducers that activate distinct transcription pathways. Toxicol Sci. 2002 Jun;67(2):182-9. [PubMed:12011477 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW: Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem Res Toxicol. 2001 Dec;14(12):1596-603. [PubMed:11743742 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Kanai N, Lu R, Bao Y, Wolkoff AW, Schuster VL: Transient expression of oatp organic anion transporter in mammalian cells: identification of candidate substrates. Am J Physiol. 1996 Feb;270(2 Pt 2):F319-25. [PubMed:8779893 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23